How We Work

Zyomyx

Back

Print

CHALLENGE

Need for low cost HIV point-of-care CD4 diagnostic tests in low-resource settings. The “gold standard” for CD4 test is flow cytometry.  However it is expensive, requires complex electronic machinery and mostly located in cities and urban areas, so there is a need for a low-cost, but accurate alternative.

PROGRAM STRATEGY

Our goal is to fund diagnostics tests across our major disease areas to drive down costs and drive up accessibility by increasing decentralization of availability to diagnostics. Accurate and timely patient CD4 counts allow doctors to initiate and monitor antiretroviral therapy to guide treatment.

PARTNER

Zyomyx
Venture backed private biotechnology company focused on HIV CD4 diagnostics

Foundation focus: Proprietary technology designed by Zyomyx that combines the benefits of specific cell capture with the ability to quantify cell count through the use of a high precision capillary assembly

INVESTMENT

Unsecured convertible note and equity
Date: May 2011; debt conversion June 2013
Co-Investors: Mylan (June 2013)
Associated funding: Additional re-investments made to develop commercialization plan and  go-to-market strategy

Visit Our Blog

Connect